{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:46:44Z","timestamp":1782910004576,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09798-8","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:59:48Z","timestamp":1782907188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event"],"prefix":"10.1007","volume":"74","author":[{"given":"Whitney Main","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Megaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamrai","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"9798_CR1","doi-asserted-by":"publisher","unstructured":"Lin X, Kang K, Chen P, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23(108). https:\/\/doi.org\/10.1186\/s12943-024-02023-w.","DOI":"10.1186\/s12943-024-02023-w"},{"key":"9798_CR2","doi-asserted-by":"publisher","unstructured":"Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(10). https:\/\/doi.org\/10.1186\/s12943-018-0928-4.","DOI":"10.1186\/s12943-018-0928-4"},{"key":"9798_CR3","doi-asserted-by":"publisher","unstructured":"Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1). https:\/\/doi.org\/10.1186\/s40425-019-0774-y.","DOI":"10.1186\/s40425-019-0774-y"},{"issue":"6","key":"9798_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s11523-023-01007-y","volume":"18","author":"S Fung","year":"2023","unstructured":"Fung S, Syed YY. Durvalumab: A Review in Advanced Biliary Tract Cancer: S. Fung, YY Syed. Target Oncol. 2023;18(6):965\u201372.","journal-title":"Target Oncol"},{"issue":"5","key":"9798_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","volume":"4","author":"S Tan","year":"2022","unstructured":"Tan S, Day D, Nicholls SJ, Segelov E. Immune checkpoint inhibitors therapy in oncology. JACC:CardioOncology State Art Rev. 2022;4(5):579\u201397. https:\/\/doi.org\/10.1016\/j.jaccao.2022.09.004.","journal-title":"JACC:CardioOncology State Art Rev"},{"key":"9798_CR6","doi-asserted-by":"publisher","unstructured":"Marco C, Simo M, Casasnovas D et al. Myasthenia gravis induced by immune checkpoint inhibitors: An Emerging neurotoxicity in Neuro-Oncology Practice: Case Series. J Clin Med, 12(130). https:\/\/doi.org\/10.3390\/jcm12010130","DOI":"10.3390\/jcm12010130"},{"issue":"6","key":"9798_CR7","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint-inhibitor related adverse events. J Immunother Cancer. 2021;9(6):e002435. https:\/\/doi.org\/10.1136\/jitc-2021-002435.","journal-title":"J Immunother Cancer"},{"key":"9798_CR8","doi-asserted-by":"publisher","unstructured":"Qin Y, Chen S, Gui Q, et al. Prognosis of Immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review. Front Neurol. 2024;15. https:\/\/doi.org\/10.3389\/fneur.2024.1372861.","DOI":"10.3389\/fneur.2024.1372861"},{"key":"9798_CR9","doi-asserted-by":"publisher","first-page":"1646231","DOI":"10.3389\/fonc.2025.1646231","volume":"15","author":"X Lin","year":"2025","unstructured":"Lin X, Liu P, Jin M, Qi G. Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis. Front Oncol. 2025;15:1646231.","journal-title":"Front Oncol"},{"issue":"9","key":"9798_CR10","doi-asserted-by":"publisher","first-page":"e011590","DOI":"10.1136\/jitc-2025-011590","volume":"13","author":"L M\u00fcller-Jensen","year":"2025","unstructured":"M\u00fcller-Jensen L, Flatz L, Ali OH, Mohr R, Lachmann N, M\u00f6dl L, Huehnchen P. HLA-A* 01: 01-B* 08: 01-C* 07: 01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis. J Immunother Cancer. 2025;13(9):e011590.","journal-title":"J Immunother Cancer"},{"issue":"suppl5","key":"9798_CR11","first-page":"S70","volume":"48","author":"SA Mayer","year":"1997","unstructured":"Mayer SA. Intensive care of the myasthenic patient. Neurology. 1997;48(suppl5):S70\u20135.","journal-title":"Neurology"},{"issue":"12","key":"9798_CR12","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1097\/00003246-200212000-00009","volume":"30","author":"P N Varelas","year":"2002","unstructured":"N Varelas P, C Chua H, Natterman J, Barmadia L, Zimmerman P, Yahia A, F Hanley D. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate. Crit Care Med. 2002;30(12):2663\u20138.","journal-title":"Crit Care Med"},{"key":"9798_CR13","doi-asserted-by":"publisher","unstructured":"Huang Y, Chen Y, Lin W, Su W, Sun Y. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020;11(634). https:\/\/doi.org\/10.3389\/fneur.2020.00643.","DOI":"10.3389\/fneur.2020.00643"},{"key":"9798_CR14","doi-asserted-by":"publisher","unstructured":"Verma N, Muhammad J, Pina Y, Peguero E, Mokhtari S. Rituximab for immune checkpoint inhibitor myasthenia gravis. 2021. Retrieved December 3, 2024, from https:\/\/doi.org\/10.7759\/cureus.16337.","DOI":"10.7759\/cureus.16337"},{"key":"9798_CR15","doi-asserted-by":"publisher","unstructured":"Cooksley T, Weaver J, McNarmara M, Lorigan P. Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but no at the same time? QJM: Int J Med 117(5):373\u20134 https:\/\/doi.org\/10.1093\/qjmed\/hcae006","DOI":"10.1093\/qjmed\/hcae006"},{"issue":"16","key":"9798_CR16","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/diagnostics14161794","volume":"14","author":"DN Lipe","year":"2024","unstructured":"Lipe DN, Qdaisat A, Krishnmani PP, et al. Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review. Diagnostics (Basel). 2024;14(16):1794\u20131794. https:\/\/doi.org\/10.3390\/diagnostics14161794.","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"9798_CR17","first-page":"4573","volume":"268","author":"I Lotan","year":"2021","unstructured":"Lotan I, Hellmann MA, Wilf-Yarkoni A, Steiner I. Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? Syst Rev J Neurol. 2021;268(12):4573\u201386.","journal-title":"Syst Rev J Neurol"},{"issue":"1","key":"9798_CR18","doi-asserted-by":"publisher","first-page":"13497","DOI":"10.1038\/s41598-020-70539-4","volume":"10","author":"L D\u00edez-Porras","year":"2020","unstructured":"D\u00edez-Porras L, Homedes C, Alberti MA, V\u00e9lez-Santamar\u00eda V, Casasnovas C. Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis. Sci Rep. 2020;10(1):13497.","journal-title":"Sci Rep"},{"issue":"1","key":"9798_CR19","doi-asserted-by":"publisher","first-page":"19523","DOI":"10.1038\/s41598-024-70373-y","volume":"14","author":"A Mazeraud","year":"2024","unstructured":"Mazeraud A, Sivanandamoorthy S, Mancusi R, Clair B, Friedman D, Fadel F, Annane D. Weaning from mechanical ventilation during myasthenic crisis, a monocentric retrospective study. Sci Rep. 2024;14(1):19523.","journal-title":"Sci Rep"},{"issue":"7","key":"9798_CR20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/archneur.65.7.929","volume":"65","author":"J Seneviratne","year":"2008","unstructured":"Seneviratne J, Mandrekar J, Wijdicks EF, Rabinstein AA. Predictors of extubation failure in myasthenic crisis. Arch Neurol. 2008;65(7):929\u201333.","journal-title":"Arch Neurol"},{"key":"9798_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/2539493","volume":"2019","author":"M Fazel","year":"2019","unstructured":"Fazel M, Jedlowski PM. Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma. Case Rep Immunol. 2019;2019:1\u20133. https:\/\/doi.org\/10.1155\/2019\/2539493.","journal-title":"Case Rep Immunol"},{"issue":"16","key":"9798_CR22","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037.","journal-title":"J Am Coll Cardiol"},{"key":"9798_CR23","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, Monestier S, Grob JJ, Scemama U, Jacquier A, Lalevee N, Barraud J, Peyrol M, Laine M, Bonello L, Paganelli F, Cohen A, Barlesi F, Ederhy S, Thuny F. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136:2085\u20137.","journal-title":"Circulation"},{"key":"9798_CR24","doi-asserted-by":"crossref","unstructured":"Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, \u2026 Moslehi J. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(1):80\u201391.","DOI":"10.1161\/CIRCULATIONAHA.118.034497"},{"key":"9798_CR25","doi-asserted-by":"publisher","unstructured":"Palaskas N, Lopez\u2010Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: Pathophysiological characteristics, diagnosis, and treatment. Journal of the American Heart Association. 2020;9(2):e013757. https:\/\/doi.org\/10.1161\/JAHA.119.013757.","DOI":"10.1161\/JAHA.119.013757"},{"key":"9798_CR26","doi-asserted-by":"crossref","unstructured":"Power JR, Dolladille C, Ozbay B, Procureur A, Ederhy S, Palaskas NL, \u2026 Salem JE. Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Eur Heart J. 2026;47(9): 1050\u20131062.","DOI":"10.1093\/eurheartj\/ehaf315"},{"key":"9798_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf192","author":"J Schulz-Menger","year":"2025","unstructured":"Schulz-Menger J, Collini V, Gr\u00f6schel J, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J Adv online publication. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf192.","journal-title":"Eur Heart J Adv online publication"},{"issue":"24","key":"9798_CR28","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for severe immune checkpoint inhibitor\u2013associated myocarditis. N Engl J Med. 2019;380(24):2377\u20139.","journal-title":"N Engl J Med"},{"key":"9798_CR29","doi-asserted-by":"publisher","unstructured":"Yin Q, Wu L, Han L, Zheng X, Rongsheng T, Li L, Bai L, Bian L. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;2023(14). https:\/\/doi.org\/10.3389\/fimmu.2023.1167975.","DOI":"10.3389\/fimmu.2023.1167975"},{"key":"9798_CR30","doi-asserted-by":"publisher","unstructured":"Walsh MJ, Dougan M. Checkpoint blockage toxicities: Insights into autoimmunity and treatment. Seminars in Immunology. 52. Published online March 2021:101473 https:\/\/doi.org\/10.1016\/j.smim.2021.101473","DOI":"10.1016\/j.smim.2021.101473"},{"key":"9798_CR31","doi-asserted-by":"publisher","unstructured":"GaoW, Lignxiang W, Shidai J, Jun L et al. Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis. J Immunother Cancer. 10(11). https:\/\/doi.org\/10.1136\/jitc-2022-005970","DOI":"10.1136\/jitc-2022-005970"},{"key":"9798_CR32","doi-asserted-by":"crossref","unstructured":"Genta S, Lajkosz K, Yee NR, Spiliopoulou P, Heirali A, Hansen AR,\u2026 Spreafico A. Autoimmune paneLs as prEdictors of toxicity in patients TReated with immune checkpoint inhibiTors (ALERT). J Exp Clin Cancer Res. 2023;42(1):276.","DOI":"10.1186\/s13046-023-02851-6"},{"key":"9798_CR33","unstructured":"National Institutes of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Institutes of Health\/National Cancer Institute; 2017."},{"issue":"11","key":"9798_CR34","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.cjca.2023.06.007","volume":"39","author":"J Kuniyoshi","year":"2023","unstructured":"Kuniyoshi J, Huang R, Choi H, Bernas M, Witina Techasatian, Nishimura Y. Immune Checkpoint Inhibitor-Induced Myocarditis with Concurrent Myasthenia Gravis. Can J Cardiol. 2023;39(11):1646\u20138. . https:\/\/doi.org\/10.1016\/j.cjca.2023.06.007","journal-title":"Can J Cardiol"},{"issue":"36","key":"9798_CR35","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy. ASCO Guideline Update J Clin oncology: official J Am Soc Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"ASCO Guideline Update J Clin oncology: official J Am Soc Clin Oncol"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09798-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:00:00Z","timestamp":1782907200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9798"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09798-8","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent obtained prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}